Frontiers in Pharmacology | Pharmacoepidemiology

Original Research

Published on 29 Jan 2025

Exploring the association between herbal medicine usage and drug-induced liver injury: insights from a nationwide population-based cohort study using SCCS in South Korea

in Pharmacoepidemiology

Taehyun Yang
Juhee Ahn
Sungho Won
Sanghun Lee

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1498124

130 views

Original Research

Accepted on 27 Jan 2025

Pharmacovigilance analysis of Polatuzumab plus Bendamustine and Rituximab treatment protocol: Identifying Comprehensive Safety Signals using FDA Database

in Pharmacoepidemiology

Fang Wu
Siliang Wang
Xihui Xu
Weihui Zhang
Jie Zhou
Runyang Niu
Wenting Cai
Yonggong Yang
Mengying Liu
Jinping Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1459067

Original Research

Accepted on 27 Jan 2025

Association between GLP-1 RAs and DPP-4 Inhibitors with biliary disorders: pharmacovigilance analysis

in Pharmacoepidemiology

Long He
Jinwei Ll
Xiong Cheng
Li Luo
Yilan Huang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1509561

Original Research

Accepted on 27 Jan 2025

Impact of levetiracetam on direct oral anticoagulant level and outcomes among older Asian patients with atrial fibrillation

in Pharmacoepidemiology

Yu-Ting Huang
Tzu-Ling Chen
Yun-Lin Huang
Ching-Hua Kuo
Yu-Fong Peng
Sung-chun Tang
Jiann-Shing Jeng
Chih-Fen Huang
Lin Shin Yi
Fang-Ju Lin

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1505665

Original Research

Published on 24 Jan 2025

Data mining and safety analysis of voriconazole in patients with a hematological malignant tumor based on the FAERS database: differences between children and adults

in Pharmacoepidemiology

Hao Li
Manxue Jiang
Xiaona Pan
Lingti Kong

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1524702

192 views

Original Research

Accepted on 23 Jan 2025

Mining and analysis of dizziness adverse event signals in postoperative analgesia patients based on the FDA adverse event reporting system database

in Pharmacoepidemiology

Fengqi Zhou
Haiou He
Zhen Zhang
Jing Gao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1488469

Systematic Review

Accepted on 07 Jan 2025

Global Bibliometric Analysis of Traditional Chinese Medicine Regulating Gut Microbiota in the Treatment of Diabetes from 2004 to 2024

in Pharmacoepidemiology

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1533984

197 views

Original Research

Published on 23 Jan 2025

A post-marketing pharmacovigilance study of triazole antifungals: adverse event data mining and analysis based on the FDA adverse event reporting system database

in Pharmacoepidemiology

Yalan Tian
Min Jin
Hong Ning

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1462510

175 views

Original Research

Accepted on 22 Jan 2025

Disproportionality Analysis of Upadacitinib-Related Adverse Events in Inflammatory Bowel Disease Using the FDA Adverse Event Reporting System Adverse Events of Upadacitinib in Inflammatory Bowel Disease: Insights from the FDA Adverse Event Reporting System Database

in Pharmacoepidemiology

Shiyi Wang
Xiaojian Wang
Jing Ding
Xudong Zhang
Hongmei Zhu
Yihong Fan
Sun Changbo

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1436183

Correction

Accepted on 22 Jan 2025

Corrigendum: Adverse Drug Events (ADEs) Risk Signal Mining Related to Eculizumab Based on the FARES Database

in Pharmacoepidemiology

Xi-Feng Wang
Lu-Ri Bao
Ta-La Hu
Rui-Feng Xu
Wu-Niri Gao
Jing-Yuan Wang
Jian-Rong Zhao
Zhen-Li Fu
Shu-Fang Wang
Yan Meng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1558930

Original Research

Accepted on 20 Jan 2025

Real-world pharmacovigilance investigation of imipenem/cilastatin: signal detection using the FDA Adverse Event Reporting System (FAERS) database

in Pharmacoepidemiology

Peng Jia
Yusen Zhou
Yuan Gao
Shangyu Wang
Jiangliu Yin
Yixiang Lian
Quanyou Lai

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1524159

Original Research

Published on 10 Jan 2025

Overweight and glucose/lipid metabolism abnormality associated with SSRIs: a pharmacovigilance study based on the FDA adverse event reporting system

in Pharmacoepidemiology

Jinming Cao
Zhicong Chen
Yan Wang
Yunpeng Ma
Zhen Yang
Jian Cai
Zhijun Xiao
Feng Xu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1517546

439 views

Editorial

Published on 10 Jan 2025

Editorial: Biologic drugs in immune-mediated inflammatory diseases, validation, drug-utilization, effectiveness, regulation, costs, and safety in the real-world

in Pharmacoepidemiology

Irma Convertino
Luciane Cruz Lopes
Nicole Pratt
Ylenia Ingrasciotta
Marco Tuccori

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1542453

254 views

Original Research

Published on 09 Jan 2025

Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database

in Pharmacoepidemiology

Xi-Feng Wang
Lu-Ri Bao
Ta-La Hu
Rui-Feng Xu
Wu-Niri Gao
Jing-Yuan Wang
Jian-Rong Zhao
Zhen-Li Fu
Yan Meng
Shu-Fang Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1440907

613 views

Original Research

Published on 08 Jan 2025

Safety of combined drug use in patients with cardiovascular and cerebrovascular diseases: an analysis based on the spontaneous reporting database of adverse drug reactions in Hubei Province

in Pharmacoepidemiology

Jia Wang
Yuhang Zhao
Zherui Chen
Rui Huang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1451713

337 views

Original Research

Published on 07 Jan 2025

Disproportionate adverse event signals of selumetinib in neurofibromatosis type I: insights from FAERS

in Pharmacoepidemiology

Lin Li

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1454418

406 views

Navigation group

Articles

Exploring the association between herbal medicine usage and drug-induced liver injury: insights from a nationwide population-based cohort study using SCCS in South Korea

Pharmacovigilance analysis of Polatuzumab plus Bendamustine and Rituximab treatment protocol: Identifying Comprehensive Safety Signals using FDA Database

Association between GLP-1 RAs and DPP-4 Inhibitors with biliary disorders: pharmacovigilance analysis

Impact of levetiracetam on direct oral anticoagulant level and outcomes among older Asian patients with atrial fibrillation

Data mining and safety analysis of voriconazole in patients with a hematological malignant tumor based on the FAERS database: differences between children and adults

Mining and analysis of dizziness adverse event signals in postoperative analgesia patients based on the FDA adverse event reporting system database

Global Bibliometric Analysis of Traditional Chinese Medicine Regulating Gut Microbiota in the Treatment of Diabetes from 2004 to 2024

A post-marketing pharmacovigilance study of triazole antifungals: adverse event data mining and analysis based on the FDA adverse event reporting system database

Disproportionality Analysis of Upadacitinib-Related Adverse Events in Inflammatory Bowel Disease Using the FDA Adverse Event Reporting System Adverse Events of Upadacitinib in Inflammatory Bowel Disease: Insights from the FDA Adverse Event Reporting System Database

Corrigendum: Adverse Drug Events (ADEs) Risk Signal Mining Related to Eculizumab Based on the FARES Database

Real-world pharmacovigilance investigation of imipenem/cilastatin: signal detection using the FDA Adverse Event Reporting System (FAERS) database

Overweight and glucose/lipid metabolism abnormality associated with SSRIs: a pharmacovigilance study based on the FDA adverse event reporting system

Editorial: Biologic drugs in immune-mediated inflammatory diseases, validation, drug-utilization, effectiveness, regulation, costs, and safety in the real-world

Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database

Safety of combined drug use in patients with cardiovascular and cerebrovascular diseases: an analysis based on the spontaneous reporting database of adverse drug reactions in Hubei Province

Disproportionate adverse event signals of selumetinib in neurofibromatosis type I: insights from FAERS